These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 15892586)

  • 1. The appealing story of HIV entry inhibitors : from discovery of biological mechanisms to drug development.
    Castagna A; Biswas P; Beretta A; Lazzarin A
    Drugs; 2005; 65(7):879-904. PubMed ID: 15892586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging drug targets for antiretroviral therapy.
    Reeves JD; Piefer AJ
    Drugs; 2005; 65(13):1747-66. PubMed ID: 16114975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV entry inhibitors: a new generation of antiretroviral drugs.
    Krambovitis E; Porichis F; Spandidos DA
    Acta Pharmacol Sin; 2005 Oct; 26(10):1165-73. PubMed ID: 16174430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV entry inhibitors: mechanisms of action and resistance pathways.
    Briz V; Poveda E; Soriano V
    J Antimicrob Chemother; 2006 Apr; 57(4):619-27. PubMed ID: 16464888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enfuvirtide: antiretroviral class 4, drug 1.
    Asboe D
    HIV Clin Trials; 2004; 5(1):1-6. PubMed ID: 15002081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Virus entry as a target for anti-HIV intervention.
    Esté JA
    Curr Med Chem; 2003 Sep; 10(17):1617-32. PubMed ID: 12871111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Highly active antiretroviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome.
    Barbaro G; Scozzafava A; Mastrolorenzo A; Supuran CT
    Curr Pharm Des; 2005; 11(14):1805-43. PubMed ID: 15892677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of HIV-1 subtype and tropism on treatment with chemokine coreceptor entry inhibitors; overview of viral entry inhibition.
    Panos G; Watson DC
    Crit Rev Microbiol; 2015; 41(4):473-87. PubMed ID: 24635642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry.
    Westby M; Smith-Burchnell C; Mori J; Lewis M; Mosley M; Stockdale M; Dorr P; Ciaramella G; Perros M
    J Virol; 2007 Mar; 81(5):2359-71. PubMed ID: 17182681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV entry inhibitors: progress in development and application.
    Lai WH; Huang L; Chen CH
    Yao Xue Xue Bao; 2010 Feb; 45(2):131-40. PubMed ID: 21348414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kinetic factors control efficiencies of cell entry, efficacies of entry inhibitors, and mechanisms of adaptation of human immunodeficiency virus.
    Platt EJ; Durnin JP; Kabat D
    J Virol; 2005 Apr; 79(7):4347-56. PubMed ID: 15767435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New advances in HIV entry inhibitors development.
    Rusconi S; Scozzafava A; Mastrolorenzo A; Supuran CT
    Curr Drug Targets Infect Disord; 2004 Dec; 4(4):339-55. PubMed ID: 15578975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An update in the development of HIV entry inhibitors.
    Rusconi S; Scozzafava A; Mastrolorenzo A; Supuran CT
    Curr Top Med Chem; 2007; 7(13):1273-89. PubMed ID: 17627557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The HIV entry inhibitors revisited.
    Leonard JT; Roy K
    Curr Med Chem; 2006; 13(8):911-34. PubMed ID: 16611075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enfuvirtide resistance mutations: impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization.
    Reeves JD; Lee FH; Miamidian JL; Jabara CB; Juntilla MM; Doms RW
    J Virol; 2005 Apr; 79(8):4991-9. PubMed ID: 15795284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progress in targeting HIV-1 entry.
    Ryser HJ; Flückiger R
    Drug Discov Today; 2005 Aug; 10(16):1085-94. PubMed ID: 16182193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemokine receptors as new molecular targets for antiviral therapy.
    Santoro F; Vassena L; Lusso P
    New Microbiol; 2004 Apr; 27(2 Suppl 1):17-29. PubMed ID: 15646061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D).
    Marozsan AJ; Kuhmann SE; Morgan T; Herrera C; Rivera-Troche E; Xu S; Baroudy BM; Strizki J; Moore JP
    Virology; 2005 Jul; 338(1):182-99. PubMed ID: 15935415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human immunodeficiency virus (HIV) entry inhibitors (CCR5 specific blockers) in development: are they the next novel therapies?
    Idemyor V
    HIV Clin Trials; 2005; 6(5):272-7. PubMed ID: 16306033
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.